drugset / Trial / NCT07151209
Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Not yet recruiting
20 enrolled
The First Affiliated Hospital with Nanjing Medical University
NaSingle-groupOpen-labelTreatment
Summary
Efficacy and safety of Iparomlimab and Tuvonralimab in combination with lenvatinib and SOX chemotherapy in potentially resectable MSI-H, dMMR locally advanced gastric or gastroesophageal junction adenocarcinoma patients: A prospective, multicenter, open-label Phase II single-arm clinical trial
Timeline
- Start
- 2025-09
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 40 mg/m2 | Oral |
| Subject | Tuvonralimab | Monoclonal antibody | 5 mg/kg | — |